Inactivation of p16(INK4) in hepatocellular carcinoma

Ai Min Hui, Michiie Sakamoto, Yae Kanai, Yoshinori Ino, Masahiro Gotoh, Jun Yokota, Setsuo Hirohashi

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

We analyzed the p16(INK4) status of 6 hepatocellular carcinoma (HCC) cell lines and 32 primary HCC tumors, including 9 early-stage tumors, to determine whether p16(INK4) tumor-suppressor gene inactivation participates in hepatocarcinogenesis. p16(INK4) was studied at its protein level through Western blotting, at its messenger RNA (mRNA) level through reverse- transcriptase polymerase chain reaction analysis (RT-PCR) and Northern blotting, and at its genomic level through Southern blotting and PCR-single- strand conformation polymorphism analysis. The p16 protein was absent from 3 of 6 cell lines (50%) and 11 of 32 primary tumors (34%), but present in noncancerous tissues, indicating that p16(INK4) is involved in hepatocarcinogenesis. Furthermore, we suggest that the p16 protein loss may contribute to the following: (1) early-stage hepatocarcinogenesis, because it was observed in 22% of early stage tumors; and (2) tumor progression, because it occurred approximately twice as often in advanced rather than in early stage tumors (40%). It was striking that neither p16(INK4) homozygous deletion and mutation nor loss of p16(INK4) mRNA expression were observed in HCC cell lines and primary tumors, including those specimens from which the p16 protein was absent except the Li7HM cell line, in which p16(INK4) mRNA was not detected. These results suggest that p16(INK4) in HCC is inactivated predominantly by posttranscriptional regulation rather than by genomic aberrations and lack of transcription.

Original languageEnglish
Pages (from-to)575-579
Number of pages5
JournalHepatology
Volume24
Issue number3
DOIs
Publication statusPublished - 1996 Sep
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Neoplasms
Cell Line
Messenger RNA
Proteins
Sequence Deletion
Gene Silencing
Southern Blotting
Tumor Cell Line
Tumor Suppressor Genes
Reverse Transcriptase Polymerase Chain Reaction
Northern Blotting
Western Blotting
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Hepatology

Cite this

Inactivation of p16(INK4) in hepatocellular carcinoma. / Hui, Ai Min; Sakamoto, Michiie; Kanai, Yae; Ino, Yoshinori; Gotoh, Masahiro; Yokota, Jun; Hirohashi, Setsuo.

In: Hepatology, Vol. 24, No. 3, 09.1996, p. 575-579.

Research output: Contribution to journalArticle

Hui, AM, Sakamoto, M, Kanai, Y, Ino, Y, Gotoh, M, Yokota, J & Hirohashi, S 1996, 'Inactivation of p16(INK4) in hepatocellular carcinoma', Hepatology, vol. 24, no. 3, pp. 575-579. https://doi.org/10.1053/jhep.1996.v24.pm0008781327
Hui, Ai Min ; Sakamoto, Michiie ; Kanai, Yae ; Ino, Yoshinori ; Gotoh, Masahiro ; Yokota, Jun ; Hirohashi, Setsuo. / Inactivation of p16(INK4) in hepatocellular carcinoma. In: Hepatology. 1996 ; Vol. 24, No. 3. pp. 575-579.
@article{417be29508f74bfe9e4246a3d4e46a39,
title = "Inactivation of p16(INK4) in hepatocellular carcinoma",
abstract = "We analyzed the p16(INK4) status of 6 hepatocellular carcinoma (HCC) cell lines and 32 primary HCC tumors, including 9 early-stage tumors, to determine whether p16(INK4) tumor-suppressor gene inactivation participates in hepatocarcinogenesis. p16(INK4) was studied at its protein level through Western blotting, at its messenger RNA (mRNA) level through reverse- transcriptase polymerase chain reaction analysis (RT-PCR) and Northern blotting, and at its genomic level through Southern blotting and PCR-single- strand conformation polymorphism analysis. The p16 protein was absent from 3 of 6 cell lines (50{\%}) and 11 of 32 primary tumors (34{\%}), but present in noncancerous tissues, indicating that p16(INK4) is involved in hepatocarcinogenesis. Furthermore, we suggest that the p16 protein loss may contribute to the following: (1) early-stage hepatocarcinogenesis, because it was observed in 22{\%} of early stage tumors; and (2) tumor progression, because it occurred approximately twice as often in advanced rather than in early stage tumors (40{\%}). It was striking that neither p16(INK4) homozygous deletion and mutation nor loss of p16(INK4) mRNA expression were observed in HCC cell lines and primary tumors, including those specimens from which the p16 protein was absent except the Li7HM cell line, in which p16(INK4) mRNA was not detected. These results suggest that p16(INK4) in HCC is inactivated predominantly by posttranscriptional regulation rather than by genomic aberrations and lack of transcription.",
author = "Hui, {Ai Min} and Michiie Sakamoto and Yae Kanai and Yoshinori Ino and Masahiro Gotoh and Jun Yokota and Setsuo Hirohashi",
year = "1996",
month = "9",
doi = "10.1053/jhep.1996.v24.pm0008781327",
language = "English",
volume = "24",
pages = "575--579",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Inactivation of p16(INK4) in hepatocellular carcinoma

AU - Hui, Ai Min

AU - Sakamoto, Michiie

AU - Kanai, Yae

AU - Ino, Yoshinori

AU - Gotoh, Masahiro

AU - Yokota, Jun

AU - Hirohashi, Setsuo

PY - 1996/9

Y1 - 1996/9

N2 - We analyzed the p16(INK4) status of 6 hepatocellular carcinoma (HCC) cell lines and 32 primary HCC tumors, including 9 early-stage tumors, to determine whether p16(INK4) tumor-suppressor gene inactivation participates in hepatocarcinogenesis. p16(INK4) was studied at its protein level through Western blotting, at its messenger RNA (mRNA) level through reverse- transcriptase polymerase chain reaction analysis (RT-PCR) and Northern blotting, and at its genomic level through Southern blotting and PCR-single- strand conformation polymorphism analysis. The p16 protein was absent from 3 of 6 cell lines (50%) and 11 of 32 primary tumors (34%), but present in noncancerous tissues, indicating that p16(INK4) is involved in hepatocarcinogenesis. Furthermore, we suggest that the p16 protein loss may contribute to the following: (1) early-stage hepatocarcinogenesis, because it was observed in 22% of early stage tumors; and (2) tumor progression, because it occurred approximately twice as often in advanced rather than in early stage tumors (40%). It was striking that neither p16(INK4) homozygous deletion and mutation nor loss of p16(INK4) mRNA expression were observed in HCC cell lines and primary tumors, including those specimens from which the p16 protein was absent except the Li7HM cell line, in which p16(INK4) mRNA was not detected. These results suggest that p16(INK4) in HCC is inactivated predominantly by posttranscriptional regulation rather than by genomic aberrations and lack of transcription.

AB - We analyzed the p16(INK4) status of 6 hepatocellular carcinoma (HCC) cell lines and 32 primary HCC tumors, including 9 early-stage tumors, to determine whether p16(INK4) tumor-suppressor gene inactivation participates in hepatocarcinogenesis. p16(INK4) was studied at its protein level through Western blotting, at its messenger RNA (mRNA) level through reverse- transcriptase polymerase chain reaction analysis (RT-PCR) and Northern blotting, and at its genomic level through Southern blotting and PCR-single- strand conformation polymorphism analysis. The p16 protein was absent from 3 of 6 cell lines (50%) and 11 of 32 primary tumors (34%), but present in noncancerous tissues, indicating that p16(INK4) is involved in hepatocarcinogenesis. Furthermore, we suggest that the p16 protein loss may contribute to the following: (1) early-stage hepatocarcinogenesis, because it was observed in 22% of early stage tumors; and (2) tumor progression, because it occurred approximately twice as often in advanced rather than in early stage tumors (40%). It was striking that neither p16(INK4) homozygous deletion and mutation nor loss of p16(INK4) mRNA expression were observed in HCC cell lines and primary tumors, including those specimens from which the p16 protein was absent except the Li7HM cell line, in which p16(INK4) mRNA was not detected. These results suggest that p16(INK4) in HCC is inactivated predominantly by posttranscriptional regulation rather than by genomic aberrations and lack of transcription.

UR - http://www.scopus.com/inward/record.url?scp=0029665280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029665280&partnerID=8YFLogxK

U2 - 10.1053/jhep.1996.v24.pm0008781327

DO - 10.1053/jhep.1996.v24.pm0008781327

M3 - Article

C2 - 8781327

AN - SCOPUS:0029665280

VL - 24

SP - 575

EP - 579

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 3

ER -